CN117752744A - Anti-fatigue pharmaceutical composition and preparation method and application thereof - Google Patents

Abstract

The application relates to the technical field of medicines, in particular to an anti-fatigue pharmaceutical composition, and a preparation method and application thereof. The pharmaceutical composition is prepared from the following components in parts by weight: 75 parts of ginseng, 50 parts of placenta hominis, 250 parts of astragalus membranaceus, 250 parts of dwarf lilyturf tuber, 250 parts of dendrobium, 50 parts of mulberry, 250 parts of hawthorn, 60 parts of pseudo-ginseng, 250 parts of lithocarpus litsea and 0.001-0.01 part of L-selenium-methylselenocysteine. The anti-fatigue pharmaceutical composition provided by the embodiment of the application has the effects of tonifying qi, activating blood and eliminating fatigue.

Description

Anti-fatigue pharmaceutical composition and preparation method and application thereof

Technical Field

The application belongs to the technical field of medicines, and particularly relates to an anti-fatigue pharmaceutical composition, and a preparation method and application thereof.

Background

Along with the acceleration of modern life rhythm, people pay more and more attention to the problems of enhancing body resistance, eliminating diseases and evil, beautifying and prolonging life. Fatigue is one of the most interesting topics. Fatigue refers to a normal physiological phenomenon that must occur when brain or physical strength reaches a certain stage, but excessive fatigue may cause harm to the human body. Therefore, the development of drugs capable of resisting fatigue is of great importance.

Disclosure of Invention

The application aims to provide an anti-fatigue pharmaceutical composition, and a preparation method and application thereof, so as to solve the technical problems.

In order to achieve the purposes of the application, the technical scheme adopted by the application is as follows:

in a first aspect, embodiments of the present application provide an anti-fatigue pharmaceutical composition, which is prepared from the following components in parts by weight:

75 parts of ginseng, 50 parts of placenta hominis, 250 parts of astragalus membranaceus, 250 parts of dwarf lilyturf tuber, 250 parts of dendrobium, 50 parts of mulberry, 250 parts of hawthorn, 60 parts of pseudo-ginseng, 250 parts of lithocarpus litsea and 0.001-0.01 part of L-selenium-methylselenocysteine.

In a second aspect, an embodiment of the present application provides an application of the above pharmaceutical composition in preparing an anti-fatigue drug, where the anti-fatigue drug includes the pharmaceutical composition, 200 parts by weight of dextrin and 10 parts by weight of steviosin.

Optionally, the anti-fatigue drug is a granule.

In a third aspect, embodiments of the present application provide a method for preparing an anti-fatigue drug, including the steps of:

providing the components of the above pharmaceutical composition;

placing Ginseng radix, placenta hominis, radix astragali, radix Ophiopogonis, herba Dendrobii, mori fructus, fructus crataegi, notoginseng radix and Litsea Coreana into a multifunctional extraction tank, adding 8 times of water, decocting for 2 times, decocting for 2 hr for 1.5 hr each time;

mixing the two extractive solutions, filtering, concentrating the filtrate under reduced pressure to obtain fluid extract with relative density of 1.05-1.10, and maintaining the operation temperature at 60deg.C;

then drying and spraying to obtain dry paste powder;

adding L-selenium-methylselenocysteine into dry paste powder, and preparing into antifatigue medicine with 200 parts by weight of dextrin and 10 parts by weight of steviosin.

Compared with the prior art, the beneficial effects of the embodiment of the application are as follows:

the anti-fatigue pharmaceutical composition provided by the embodiment of the application has the effects of tonifying qi, activating blood and eliminating fatigue.

Drawings

In order to more clearly illustrate the technical solutions of the embodiments of the present application, the following description will briefly introduce the drawings that are needed in the embodiments or the description of the prior art, it is obvious that the drawings in the following description are only some embodiments of the present application, and that other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.

Fig. 1 is a method flowchart of a preparation method of an anti-fatigue drug according to an embodiment of the present application.

Detailed Description

In order to make the technical problems, technical schemes and beneficial effects to be solved by the present application more clear, the present application is further described in detail below with reference to the embodiments. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the present application.

The embodiment of the application provides an anti-fatigue pharmaceutical composition which is prepared from the following components in parts by weight: 75 parts of ginseng, 50 parts of placenta hominis, 250 parts of astragalus membranaceus, 250 parts of dwarf lilyturf tuber, 250 parts of dendrobium, 50 parts of mulberry, 250 parts of hawthorn, 60 parts of pseudo-ginseng, 250 parts of lithocarpus litsea and 0.001-0.01 part of L-selenium-methylselenocysteine.

The pharmaceutical composition provided by the embodiment of the application has the effects of tonifying qi, activating blood and eliminating fatigue.

In some embodiments, there is also provided the use of the above pharmaceutical composition in the preparation of an anti-fatigue medicament, for example, the anti-fatigue medicament comprises the above pharmaceutical composition and 200 parts by weight of dextrin and 10 parts by weight of steviosin. Wherein dextrin and steviosin are used as auxiliary materials.

Optionally, the anti-fatigue drug is a granule.

In some embodiments of the present application, an anti-fatigue pharmaceutical composition is made from the following components by weight: 7.5kg of ginseng, 5kg of placenta hominis, 25kg of astragalus membranaceus, 25kg of dwarf lilyturf tuber, 25kg of dendrobium, 5kg of mulberry, 25kg of hawthorn, 6kg of pseudo-ginseng, 25kg of lithocarpus litsea and 1.0g of L-selenium-methylselenocysteine. The anti-fatigue medicine comprises the medicine composition, 20kg of dextrin and 1kg of steviosin.

For example, as shown in fig. 1, the preparation method of the anti-fatigue drug comprises the following steps:

s110, providing the components of the pharmaceutical composition according to any of the above embodiments.

For example, the pharmaceutical composition is made from the following components by weight: 7.5kg of ginseng, 5kg of placenta hominis, 25kg of astragalus membranaceus, 25kg of dwarf lilyturf tuber, 25kg of dendrobium, 5kg of mulberry, 25kg of hawthorn, 6kg of pseudo-ginseng, 25kg of lithocarpus litsea and 1.0g of L-selenium-methylselenocysteine.

S120, putting ginseng, placenta hominis, astragalus membranaceus, dwarf lilyturf tuber, dendrobium, mulberry, hawthorn, pseudo-ginseng and lithocarpus litsea in a multifunctional extraction tank, adding 8 times of water, and decocting for 2 times, wherein the first time is 2 hours, and each time is 1.5 hours.

S130, combining and filtering the two extracting solutions, concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.05-1.10, and maintaining the operation temperature at 60 ℃.

And S140, drying and spraying to obtain dry paste powder.

S150, adding L-selenium-methyl selenocysteine into the dry paste powder to obtain the medicinal composition, and then preparing the medicinal composition into an anti-fatigue medicament together with 20kg of dextrin and 1kg of steviosin. Wherein dextrin and steviosin are used as auxiliary materials. For example, it can be made into 20000 bags (6 g/bag).

The pharmaceutical composition and the anti-fatigue drug provided by the embodiment of the application have the effects of tonifying qi, activating blood and eliminating fatigue.

The following description is made with reference to specific embodiments.

Example 1: the first anti-fatigue medicine is prepared from the following components in parts by weight by adopting the preparation method:

example 2: the second anti-fatigue medicine is prepared from the following components in parts by weight:

example 3: the third anti-fatigue medicine is prepared from the following components in parts by weight:

example 4: the fourth anti-fatigue medicine is prepared from the following components in parts by weight:

200 cases were subjected to a comparative test using the first anti-fatigue agent obtained in example 1, of which women were 100 and men were 100.

Crowd selection criteria: people with long-term working pressure, irregular sleep, easy illness, dry eyes and other diseases. The population was continuously observed one week prior to the experiment and symptom changes were recorded. The animals were randomized into two groups, the experimental and control groups.

The experimental group took the first anti-fatigue drug of example 1, and the control group took at least one of the second anti-fatigue drug, the third anti-fatigue drug, and the fourth anti-fatigue drug.

Curative effect condition judgment standard:

the method is effective: after taking the product, the sleep quality is improved, the mood is relaxed, the resistance is enhanced, the dry eyes are relieved, and the deterioration of cancer patients is relieved.

Invalidation: after taking the product, the effect is not obvious without obvious change.

The test results are shown in table one below:

list one

	Experimental group	Control group
			Number of examples	100	100
Male men	50	50
			Female woman	50	50
Number of effective cases	99	68
			Number of invalid cases	1	32
Effective rate of	99％	68％

The treatment effect is as follows: from the above results, it is evident that the anti-fatigue medicine provided by the examples of the present application is significantly superior to other formulations in anti-aging and anti-fatigue treatments.

It should be understood that, in various embodiments of the present application, the sequence number of each process does not mean that the sequence of execution is sequential, and some or all of the steps may be executed in parallel or sequentially, where the execution sequence of each process should be determined by its functions and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.

The terminology used in the embodiments of the application is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. As used in this application and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.

The weights of the relevant components mentioned in the embodiments of the present application may refer not only to specific contents of the components, but also to the proportional relationship between the weights of the components, and thus, any ratio of the contents of the relevant components according to the embodiments of the present application may be enlarged or reduced within the scope disclosed in the embodiments of the present application. Specifically, the mass described in the specification of the examples of the present application may be a mass unit known in the chemical industry such as μ g, mg, g, kg.

The foregoing description of the preferred embodiments of the present application is not intended to be limiting, but is intended to cover any and all modifications, equivalents, and alternatives falling within the spirit and principles of the present application.

Claims (4)

1. The anti-fatigue pharmaceutical composition is characterized by being prepared from the following components in parts by weight:

75 parts of ginseng, 50 parts of placenta hominis, 250 parts of astragalus membranaceus, 250 parts of dwarf lilyturf tuber, 250 parts of dendrobium, 50 parts of mulberry, 250 parts of hawthorn, 60 parts of pseudo-ginseng, 250 parts of lithocarpus litsea and 0.001-0.01 part of L-selenium-methylselenocysteine.

2. The use of a pharmaceutical composition according to claim 1 for the preparation of an anti-fatigue drug, wherein the anti-fatigue drug comprises the pharmaceutical composition together with 200 parts by weight of dextrin and 10 parts by weight of steviosin.

3. The use according to claim 2, wherein the anti-fatigue agent is in the form of granules.

4. The preparation method of the anti-fatigue medicine is characterized by comprising the following steps:

providing the components of the pharmaceutical composition of claim 1;

placing the ginseng, the placenta hominis, the astragalus membranaceus, the dwarf lilyturf tuber, the dendrobium, the mulberry, the hawthorn, the pseudo-ginseng and the lithocarpus litsea in a multifunctional extraction tank, adding 8 times of water, decocting and extracting for 2 times, wherein the first time is 2 hours, and each time is 1.5 hours;

mixing the two extractive solutions, filtering, concentrating the filtrate under reduced pressure to obtain fluid extract with relative density of 1.05-1.10, and maintaining the operation temperature at 60deg.C;

then drying and spraying to obtain dry paste powder;

adding the L-selenium-methylselenocysteine into the dry paste powder, and then preparing the anti-fatigue medicine with 200 parts by weight of dextrin and 10 parts by weight of steviosin.